Sansure Biotech マネジメント

マネジメント基準チェック /34

Sansure Biotechの CEO はLizhong Daiで、 Jul2019年に任命され、の在任期間は 5.33年です。は、会社の株式の33.21%を直接所有しており、その価値はCN¥ 4.63B 。経営陣と取締役会の平均在任期間はそれぞれ5.3年と5.3年です。

主要情報

Lizhong Dai

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	5.3yrs
CEOの所有権	33.2%
経営陣の平均在職期間	5.3yrs
取締役会の平均在任期間	5.3yrs

経営陣の近況

Recent updates

Sansure Biotech's (SHSE:688289) Problems Go Beyond Weak Profit

Nov 03

Sansure Biotech Inc.'s (SHSE:688289) 39% Price Boost Is Out Of Tune With Earnings

Oct 09

Why Sansure Biotech's (SHSE:688289) Soft Earnings Are Just The Beginning Of Its Problems

May 03

Sansure Biotech Inc.'s (SHSE:688289) Business Is Trailing The Industry But Its Shares Aren't

Apr 26

Sansure Biotech's (SHSE:688289) Returns On Capital Are Heading Higher

Feb 28

CEO（最高経営責任者

Lizhong Dai (56 yo)

5.3yrs

在職期間

CN¥991,000

報酬

Mr. Lizhong Dai is Chairman of the Board and General Manager of Sansure Biotech Inc. from July 2019.

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Lizhong Dai	Chairman of the Board & GM	5.3yrs	CN¥991.00k	33.21% CN¥ 4.6b
Peng Zhu	CFO, Deputy GM	5.3yrs	CN¥1.14m	0.067% CN¥ 9.3m
Xialin Yu	Deputy GM & Director	5.3yrs	CN¥675.40k	0.026% CN¥ 3.7m
Xu Fan	Deputy GM & Director	5.3yrs	CN¥1.07m	0.054% CN¥ 7.5m
Jia Liu	Deputy GM & Director	no data	CN¥1.03m	0.035% CN¥ 4.9m
Zhongping Deng	Deputy General Manager	5.8yrs	CN¥973.70k	0.019% CN¥ 2.6m
Jun Zhou	Deputy General Manager	5.3yrs	CN¥1.11m	0.016% CN¥ 2.2m
Liu Kai	Deputy General Manager	3.3yrs	CN¥1.90m	0.026% CN¥ 3.6m
Jian Zhu	Deputy General Manager	3.3yrs	CN¥3.05m	0.025% CN¥ 3.4m
Haixiao Wang	Deputy General Manager	2.3yrs	CN¥2.15m	0.041% CN¥ 5.7m
Xiaoyan Xiong	Deputy General Manager	2.1yrs	CN¥868.70k	0.022% CN¥ 3.1m

5.3yrs

平均在職期間

47yo

平均年齢

経験豊富な経営陣: 688289の経営陣は経験豊富で経験豊富です（平均在職期間は5.3年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Lizhong Dai	Chairman of the Board & GM	5.3yrs	CN¥991.00k	33.21% CN¥ 4.6b
Peng Zhu	CFO, Deputy GM	4.8yrs	CN¥1.14m	0.067% CN¥ 9.3m
Xialin Yu	Deputy GM & Director	5.3yrs	CN¥675.40k	0.026% CN¥ 3.7m
Xu Fan	Deputy GM & Director	4.1yrs	CN¥1.07m	0.054% CN¥ 7.5m
Jia Liu	Deputy GM & Director	2.3yrs	CN¥1.03m	0.035% CN¥ 4.9m
Wu Tan	Chairman of Supervisory Board	5.3yrs	データなし	0.035% CN¥ 4.9m
Ya Cao	Independent Director	5.3yrs	CN¥75.00k	データなし
Yuan Fang	Director	5.3yrs	データなし	データなし
Ling Lin	Supervisor	2.3yrs	データなし	0.00040% CN¥ 55.7k

5.3yrs

平均在職期間

45yo

平均年齢

経験豊富なボード: 688289の取締役会は経験豊富であると考えられます ( 5.3年の平均在任期間)。

Sansure Biotech マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Sansure Biotech Inc., Annual General Meeting, May 17, 2024

Less than half of directors are independent

No independent directors

Recent updates

Sansure Biotech's (SHSE:688289) Problems Go Beyond Weak Profit

New major risk - Dividend sustainability

Third quarter 2024 earnings released: EPS: CN¥0.069 (vs CN¥0.34 in 3Q 2023)

Investor sentiment deteriorates as stock falls 18%

Sansure Biotech Inc.'s (SHSE:688289) 39% Price Boost Is Out Of Tune With Earnings

Sansure Biotech (SHSE:688289) Could Be Struggling To Allocate Capital

Sansure Biotech Inc. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 30%

Is Sansure Biotech (SHSE:688289) A Risky Investment?

Second quarter 2024 earnings released: EPS: CN¥0.13 (vs CN¥0.058 in 2Q 2023)

Sansure Biotech Inc. (SHSE:688289) Investors Are Less Pessimistic Than Expected

Sansure Biotech Inc. to Report First Half, 2024 Results on Aug 27, 2024

Sansure Biotech (SHSE:688289) May Have Issues Allocating Its Capital

Why Sansure Biotech's (SHSE:688289) Soft Earnings Are Just The Beginning Of Its Problems

Sansure Biotech Inc., Annual General Meeting, May 17, 2024

First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.10 in 1Q 2023)

Sansure Biotech Inc.'s (SHSE:688289) Business Is Trailing The Industry But Its Shares Aren't

Sansure Biotech Inc. to Report Q1, 2024 Results on Apr 27, 2024

Full year 2023 earnings released: EPS: CN¥0.63 (vs CN¥3.31 in FY 2022)

Sansure Biotech's (SHSE:688289) Returns On Capital Are Heading Higher

Investor sentiment improves as stock rises 17%

Now 26% overvalued after recent price rise

Third quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.81 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.058 (vs CN¥0.81 in 2Q 2022)

Sansure Biotech Inc. to Report First Half, 2023 Results on Aug 30, 2023

Investor sentiment deteriorates as stock falls 19%

Full year 2022 earnings released: EPS: CN¥3.31 (vs CN¥3.79 in FY 2021)

Full year 2022 earnings released: EPS: CN¥3.45 (vs CN¥3.79 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.81 (vs CN¥1.07 in 3Q 2021)

Sansure Biotech Inc. (SHSE:688289) announces an Equity Buyback for CNY 200 million worth of its shares.

Second quarter 2022 earnings released: EPS: CN¥0.81 (vs CN¥0.84 in 2Q 2021)

Now 21% undervalued

Investor sentiment improved over the past week

Now 20% undervalued after recent price drop

No independent directors

Now 24% undervalued after recent price drop

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2021 earnings released: EPS CN¥1.59 (vs CN¥2.09 in 3Q 2020)

Investor sentiment deteriorated over the past week

Gree Real Estate's Unit Scraps Plans to Sell Stake in Biological Engineering Firm

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥1.56 (vs CN¥0.54 in 1Q 2020)

Sansure Biotech Inc. Provides Earnings Guidance for the First Quarter of 2021

Full year 2020 earnings released: EPS CN¥7.01 (vs CN¥0.11 in FY 2019)

New 90-day low: CN¥98.66

New 90-day high: CN¥137

Sansure Biotech Inc. to Report Q3, 2020 Results on Oct 30, 2020

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34